Can genome engineering be used to target cancer-associated enhancers?

Matthew R. Grimmer, Peggy J. Farnham

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Transcriptional misregulation is involved in the development of many diseases, especially neoplastic transformation. Distal regulatory elements, such as enhancers, play a major role in specifying cell-specific transcription patterns in both normal and diseased tissues, suggesting that enhancers may be prime targets for therapeutic intervention. By focusing on modulating gene regulation mediated by cell type-specific enhancers, there is hope that normal epigenetic patterning in an affected tissue could be restored with fewer side effects than observed with treatments employing relatively nonspecific inhibitors such as epigenetic drugs. New methods employing genomic nucleases and site-specific epigenetic regulators targeted to specific genomic regions, using either artificial DNA-binding proteins or RNA-DNA interactions, may allow precise genome engineering at enhancers. However, this field is still in its infancy and further refinements that increase specificity and efficiency are clearly required.

Original languageEnglish (US)
Pages (from-to)493-501
Number of pages9
JournalEpigenomics
Volume6
Issue number5
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Epigenomics
Genome
Neoplasms
DNA-Binding Proteins
RNA
DNA
Pharmaceutical Preparations
Genes
Therapeutics

Keywords

  • CRISPRs
  • DNA methylation
  • enhancers
  • epigenetic therapy
  • gene expression
  • genome engineering
  • genomic nuclease
  • histone modifications
  • TALENs
  • ZFNs

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Can genome engineering be used to target cancer-associated enhancers? / Grimmer, Matthew R.; Farnham, Peggy J.

In: Epigenomics, Vol. 6, No. 5, 01.10.2014, p. 493-501.

Research output: Contribution to journalArticle

Grimmer, Matthew R. ; Farnham, Peggy J. / Can genome engineering be used to target cancer-associated enhancers?. In: Epigenomics. 2014 ; Vol. 6, No. 5. pp. 493-501.
@article{8005f4370e9e419cb7b3a4dd29b2cbff,
title = "Can genome engineering be used to target cancer-associated enhancers?",
abstract = "Transcriptional misregulation is involved in the development of many diseases, especially neoplastic transformation. Distal regulatory elements, such as enhancers, play a major role in specifying cell-specific transcription patterns in both normal and diseased tissues, suggesting that enhancers may be prime targets for therapeutic intervention. By focusing on modulating gene regulation mediated by cell type-specific enhancers, there is hope that normal epigenetic patterning in an affected tissue could be restored with fewer side effects than observed with treatments employing relatively nonspecific inhibitors such as epigenetic drugs. New methods employing genomic nucleases and site-specific epigenetic regulators targeted to specific genomic regions, using either artificial DNA-binding proteins or RNA-DNA interactions, may allow precise genome engineering at enhancers. However, this field is still in its infancy and further refinements that increase specificity and efficiency are clearly required.",
keywords = "CRISPRs, DNA methylation, enhancers, epigenetic therapy, gene expression, genome engineering, genomic nuclease, histone modifications, TALENs, ZFNs",
author = "Grimmer, {Matthew R.} and Farnham, {Peggy J.}",
year = "2014",
month = "10",
day = "1",
doi = "10.2217/epi.14.30",
language = "English (US)",
volume = "6",
pages = "493--501",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Can genome engineering be used to target cancer-associated enhancers?

AU - Grimmer, Matthew R.

AU - Farnham, Peggy J.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Transcriptional misregulation is involved in the development of many diseases, especially neoplastic transformation. Distal regulatory elements, such as enhancers, play a major role in specifying cell-specific transcription patterns in both normal and diseased tissues, suggesting that enhancers may be prime targets for therapeutic intervention. By focusing on modulating gene regulation mediated by cell type-specific enhancers, there is hope that normal epigenetic patterning in an affected tissue could be restored with fewer side effects than observed with treatments employing relatively nonspecific inhibitors such as epigenetic drugs. New methods employing genomic nucleases and site-specific epigenetic regulators targeted to specific genomic regions, using either artificial DNA-binding proteins or RNA-DNA interactions, may allow precise genome engineering at enhancers. However, this field is still in its infancy and further refinements that increase specificity and efficiency are clearly required.

AB - Transcriptional misregulation is involved in the development of many diseases, especially neoplastic transformation. Distal regulatory elements, such as enhancers, play a major role in specifying cell-specific transcription patterns in both normal and diseased tissues, suggesting that enhancers may be prime targets for therapeutic intervention. By focusing on modulating gene regulation mediated by cell type-specific enhancers, there is hope that normal epigenetic patterning in an affected tissue could be restored with fewer side effects than observed with treatments employing relatively nonspecific inhibitors such as epigenetic drugs. New methods employing genomic nucleases and site-specific epigenetic regulators targeted to specific genomic regions, using either artificial DNA-binding proteins or RNA-DNA interactions, may allow precise genome engineering at enhancers. However, this field is still in its infancy and further refinements that increase specificity and efficiency are clearly required.

KW - CRISPRs

KW - DNA methylation

KW - enhancers

KW - epigenetic therapy

KW - gene expression

KW - genome engineering

KW - genomic nuclease

KW - histone modifications

KW - TALENs

KW - ZFNs

UR - http://www.scopus.com/inward/record.url?scp=84913608232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913608232&partnerID=8YFLogxK

U2 - 10.2217/epi.14.30

DO - 10.2217/epi.14.30

M3 - Article

C2 - 25431942

AN - SCOPUS:84913608232

VL - 6

SP - 493

EP - 501

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 5

ER -